Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study finds common genetic target may halt breast cancer cell growth

2.

More pain, more gain? New biopsy technique found to improve prostate cancer detection

3.

Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.

4.

An effective treatment for a rare but deadly form of cancer

5.

Atezolizumab + Cabozantinib Postpones mCRPC Progression.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot